We’re heading to Denver for @ASNKidney #KidneyWk to share new research on rilparencel, our investigational autologous cell therapy, including non-clinical research and a pooled analysis from our Phase 2 studies. Learn more ↓

How might cell therapy work in CKD? At #KidneyWk, we’ll share 8 abstracts exploring that question, from non-clinical CKD models, drug product characterization, and more. investors.prokidney.com/news… #CKD #CellTherapy

For people with advanced #CKD, the biggest threat is often cardiovascular disease, not kidney failure. On #WorldHeartDay, we're recognizing the close connection between heart and kidney health. #KidneyHealth

The risk factors highlighted during #CholesterolEducationMonth, including diabetes, high blood pressure and metabolic disease, are also leading drivers of #CKD. Because CKD often develops without symptoms, many people don't know they have it. Learn more: bit.ly/4hhezMl

Our Boston team assembled nutritional starter kits for CKD patients across New England — recipe cards, measuring spoons, jar openers, educational materials and more. Thanks to @NKFNewEngland for bringing the ingredients and for everything they do for #CKD patients. #KidneyHealth

Orange pom-poms, catch on the field, and Sidney the Kidney. Thanks to @WSDashBaseball and @nkfcarolinas for a great Sunday at Truist Stadium, and for the kidney health resources they shared with fans all afternoon. #KidneyHealth #WinstonSalem

Dialysis often means three to four hours in a chair, three times a week, then feeling too exhausted to work. On the Vanguards of Health Care podcast, our CEO on why ProKidney focuses on preserving kidney function. bit.ly/4xk1sQX #CKD #KidneyHealth

Sunday Fun Day at Truist Stadium this weekend. Our team will be there with @WSDashBaseball and @nkfcarolinas, who’ll be there with kidney health resources on site. A portion from every ticket purchased through their link supports NKF’s work in NC. #KidneyHealth #WinstonSalem

#CKD therapies like SGLT2 inhibitors, finerenone and GLP-1 RAs have given patients more ways to slow progression. Rilparencel, our investigational cell therapy, is being studied as a potential addition.

Today is National Patient Advocacy Day. In kidney care, advocates help patients understand their options, find resources and make their voices heard. So much in #CKD is learned from patients themselves. To everyone standing alongside them, thank you. #KidneyHealth

August is National Minority Donor Awareness Month. More than 100,000 people in the US are waiting for a transplant, and 60% are from racial and ethnic minority communities. A reminder of why registration and equitable access matter. #KidneyHealth

New on @BBGIntelligence's Vanguards of Health Care: our CEO Bruce Culleton, MD on advanced #CKD, why patients still progress despite better care and how rilparencel, our investigational cell therapy, aims to preserve function. bit.ly/4xk1sQX

Big moment for our team: a group of well-deserved promotions across ProKidney. 👏 These are the people turning bold science into real progress for patients with advanced CKD and type 2 diabetes — and raising the bar every step of the way. #TeamProKidney #BiotechCareers

Most #CKD therapies aim to slow progression. Rilparencel, our investigational cell therapy, takes a different approach, using a patient’s own kidney cells to help preserve function. Learn more about our clinical trial: hopeforckd.com/ #ClinicalTrials #KidneyHealth

This #ChronicDiseaseDay: chronic kidney disease is one of the most common chronic conditions, affecting millions of Americans. In advanced #CKD, the goal is preserving kidney function, which drives the work we do every day. Learn more: prokidney.com/our-technology

We recently welcomed leaders from @ForsythTechCC  and Greater Winston-Salem, Inc. to our facility to talk growth, talent and the future of life sciences in the Triad. ProKidney's growth is rooted here, and we're proud to help build what's next.  #WinstonSalem #Biotech

Today, ProKidney joins in observing #Juneteenth — a day to reflect on the history, contributions and continued progress of the Black community in the United States.

Kathy and Paula co-chair ProKidney's Patient Advisory Board, bringing patient voice into how our Phase 3 trial of rilparencel, our investigational cell therapy, is designed. The result: a trial that reflects the full community living with advanced #CKD.

We're pleased to introduce Kenneth Locke as ProKidney's new Chief Technical Officer and Site Head for Winston-Salem. Ken brings deep experience scaling cell and gene therapy programs from clinical development through commercial launch. Welcome to the team! #leadership

The 63rd @ERAkidney Congress kicks off June 3 in Glasgow. We will be there connecting with the global nephrology community. #CKD #ERA26